Curcumin: the Indian solid gold.

Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Advances in Experimental Medicine and Biology (Impact Factor: 2.01). 02/2007; 595:1-75. DOI: 10.1007/978-0-387-46401-5_1
Source: PubMed

ABSTRACT Turmeric, derived from the plant Curcuma longa, is a gold-colored spice commonly used in the Indian subcontinent, not only for health care but also for the preservation of food and as a yellow dye for textiles. Curcumin, which gives the yellow color to turmeric, was first isolated almost two centuries ago, and its structure as diferuloylmethane was determined in 1910. Since the time of Ayurveda (1900 Bc) numerous therapeutic activities have been assigned to turmeric for a wide variety of diseases and conditions, including those of the skin, pulmonary, and gastrointestinal systems, aches, pains, wounds, sprains, and liver disorders. Extensive research within the last half century has proven that most of these activities, once associated with turmeric, are due to curcumin. Curcumin has been shown to exhibit antioxidant, anti-inflammatory, antiviral, antibacterial, antifungal, and anticancer activities and thus has a potential against various malignant diseases, diabetes, allergies, arthritis, Alzheimer's disease, and other chronic illnesses. These effects are mediated through the regulation of various transcription factors, growth factors, inflammatory cytokines, protein kinases, and other enzymes. Curcumin exhibits activities similar to recently discovered tumor necrosis factor blockers (e.g., HUMIRA, REMICADE, and ENBREL), a vascular endothelial cell growth factor blocker (e.g., AVASTIN), human epidermal growth factor receptor blockers (e.g., ERBITUX, ERLOTINIB, and GEFTINIB), and a HER2 blocker (e.g., HERCEPTIN). Considering the recent scientific bandwagon that multitargeted therapy is better than monotargeted therapy for most diseases, curcumin can be considered an ideal "Spice for Life".

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The need for low toxicity adjuncts to standard care chemotherapy in inoperable colorectal cancer, with potential to improve outcomes and decrease the side-effect burden, is well recognised. Addition of the low toxicity diet-derived agent, curcumin (the active ingredient of turmeric), to standard oxaliplatin-based therapy has shown promise in numerous pre-clinical studies. This study is the first to combine daily oral curcumin with standard care FOLFOX-based (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in colorectal cancer patients with inoperable liver metastases: the CUFOX trial. CUFOX comprises a Phase 1 dose-escalation study (3 + 3 + 3 design) to determine an acceptable target dose of curcumin with which to safely proceed to a Phase IIa open-labelled randomised controlled trial. Thirty three participants with histological or cytological confirmation of inoperable colorectal cancer will then be randomised to oxaliplatin-based chemotherapy with the addition of daily oral curcumin at the target dose determined in Phase I, or to standard care oxaliplatin-based chemotherapy alone (recruiting at a ratio of 2:1). Primary outcome measures will be the determination of a target dose which is both safe and tolerable for long-term administration to individuals in receipt of first-line oxaliplatin-based chemotherapy for inoperable colorectal cancer. Secondary outcome measures will include observation of any changes in neuropathic side-effects of chemotherapy, improvement to progression-free or overall survival and identification of putative efficacy biomarkers in plasma. The results will be disseminated via presentation at national and international conferences, via publication in appropriate peer-reviewed journals and via the Cancer Research UK/Department of Health Experimental Cancer Medicine Centre Network. This trial has full ethical and institutional approval, and commenced recruitment in February 2012. ( NCT01490996 , registered 7(th) December 2011), European Drug Regulating Authorities (EudraCT 2011-002289-19, registered 13(th) May 2011), UKCRN ID#10672.
    Trials 03/2015; 16(1). DOI:10.1186/s13063-015-0641-1 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To investigate the antioxidant properties of curcumin pyrazole derivatives using different in-vitro models and hypoglycemic potential by gluconeogenesis studies. Methods: Antioxidant ability of curcumin pyrazole derivatives was evaluated by using DPPH, nitric oxide, superoxide anion scavenging and lipid peroxidation assays comparing with standard, ascorbic acid (AA). The hypoglycemic effects of the compounds (3a-3e) were assessed by gluconeogenesis inhibition assay using rat liver slices comparing with standard, Insulin. Results: Compounds demonstrated strong scavenging activities against 2, 2-diphenyl, 2-picryl hydrazyl (DPPH), nitric oxide, superoxide anion radicals and also effectively inhibited lipid peroxidation. Compounds 3a, 3b and 3e exhibited significant activity in quenching DPPH, superoxide anion radical, nitric oxide and showed anti-lipid peroxidation. Other compounds 3c and 3d showed moderate activities. The gluconeogenesis inhibitory effects were more pronounced with compounds 3a and 3b compared to compounds 3c, 3d and 3e. Conclusion: Curcumin pyrazole derivatives showed considerable antioxidant activity against free radicals and lipid peroxidation. They exhibited significant IC50 values and thus can promote prominent protection against oxidative damage. The compounds 3a and 3b could be promising hypoglycemic agents as they are capable of lowering blood glucose by inhibiting gluconeogenesis and can be selected for further in-vitro and in vivo anti-diabetic investigations.
    International Journal of Pharmacy and Pharmaceutical Sciences 01/2015; 7(4):244-249. · 1.59 Impact Factor
  • Source
    Horizons in Cancer Research. Volume 55, Edited by Hiroto S. Watanabe, 01/2014: chapter 6: pages 135-149; Nova Publisher., ISBN: 978-1-63463-247-8

Full-text (2 Sources)

Available from
Apr 15, 2015